Posted by Michael Wonder on 13 Apr 2026
Ifinatamab deruxtecan granted priority review in the US for adult patients with previously treated extensive-stage small cell lung cancer who experienced disease progression on or after platinum-based chemotherapy
13 April 2026 - Based on results from IDeate-Lung01 Phase 2 trial, with support from IDeate-PanTumor01 Phase 1/2 trial.
Daiichi Sankyo and Merck's biologics license application for ifinatamab deruxtecan has been accepted and granted priority review by the US FDA for the treatment of adult patients with extensive-stage small cell lung cancer with disease progression on or after platinum-based chemotherapy.
